Plasma Protein Therapeutics Association

Based in MD

🤖

AI Overview

With $1.4M in lobbying spend across 29 quarterly filings, Plasma Protein Therapeutics Association is a significant lobbying presence. They deploy 21 individual lobbyists Their lobbying covers 5 issue areas. Active from 2018 to 2025.

$1.4M

Total Spend

Years Active

Firms Hired

Lobbyists Deployed

Issues Lobbied

Spending Trend

View as table

Year	Lobbying Spend
2018	$150K
2019	$200K
2020	$200K
2021	$200K
2022	$100K
2023	$200K
2024	$200K
2025	$200K

Issues Lobbied

Taxation Health Issues Medicare/Medicaid Budget/Appropriations Trade

Lobbying Firms

Williams and Jensen, PLLC

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Taxation, Health Issues, Medicare/Medicaid, Budget/Appropriations, Trade

Comprehensive Tax reform; Orphan Drug Tax and Credit; Research and Development Tax Credit.

Drug safety and drug counterfeiting; drug importation; H.R. 4724, Medicare IVIG Access Enhancement Act.

Payment policies for Medicare Part B prescription drugs; Medicare drug coverage and payment policy; for plasma products.

Payment policies for Medicare Part B prescription drugs; Medicare drug coverage and payment policies for plasma protein products.

Drug safety and drug counterfeiting; drug importation; H.R. 4724, Medicare IVIG Access Enhancement Act. Policies affecting pre-existing condition protections.

Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.

Drug safety and drug counterfeiting; Medicare IVIG Access Enhancement Act; Policies affecting pre-existing condition protections; Drug importation including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act.

Drug safety and drug counterfeiting; H.R. 2905, Medicare IVIG Access Enhancement Act; Policies affecting pre-existing condition protections; Drug importation including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act; S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019; Supply of intravenous immunoglobulin.

Showing 8 of 20 unique descriptions from filings.